Sterically Stabilised Polymeric Mesoporous Silica Nanoparticles Improve Doxorubicin Efficiency: Tailored Cancer Therapy
The fruition, commercialisation and clinical application combining nano-engineering, nanomedicine and material science for utilisation in drug delivery is becoming a reality. The successful integration of nanomaterial in nanotherapeutics requires their critical development to ensure physiological an...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/25/3/742 |
_version_ | 1818480970579312640 |
---|---|
author | Thashini Moodley Moganavelli Singh |
author_facet | Thashini Moodley Moganavelli Singh |
author_sort | Thashini Moodley |
collection | DOAJ |
description | The fruition, commercialisation and clinical application combining nano-engineering, nanomedicine and material science for utilisation in drug delivery is becoming a reality. The successful integration of nanomaterial in nanotherapeutics requires their critical development to ensure physiological and biological compatibility. Mesoporous silica nanoparticles (MSNs) are attractive nanocarriers due to their biodegradable, biocompatible, and relative malleable porous frameworks that can be functionalized for enhanced targeting and delivery in a variety of disease models. The optimal formulation of an MSN with polyethylene glycol (2% and 5%) and chitosan was undertaken, to produce sterically stabilized, hydrophilic MSNs, capable of efficient loading and delivery of the hydrophobic anti-neoplastic drug, doxorubicin (DOX). The pH-sensitive release kinetics of DOX, together with the anticancer, apoptosis and cell-cycle activities of DOX-loaded MSNs in selected cancer cell lines were evaluated. MSNs of 36−60 nm in size, with a pore diameter of 9.8 nm, and a cumulative surface area of 710.36 m<sup>2</sup>/g were produced. The 2% pegylated MSN formulation (PCMSN) had the highest DOX loading capacity (0.98 mg<sub>dox</sub>/mg<sub>msn</sub>), and a sustained release profile over 72 h. Pegylated-drug nanoconjugates were effective at a concentration range between 20−50 μg/mL, inducing apoptosis in cancer cells, and affirming their potential as effective drug delivery vehicles. |
first_indexed | 2024-12-10T11:29:12Z |
format | Article |
id | doaj.art-d5ce7a14a0af4688880aebab6e7286fd |
institution | Directory Open Access Journal |
issn | 1420-3049 |
language | English |
last_indexed | 2024-12-10T11:29:12Z |
publishDate | 2020-02-01 |
publisher | MDPI AG |
record_format | Article |
series | Molecules |
spelling | doaj.art-d5ce7a14a0af4688880aebab6e7286fd2022-12-22T01:50:39ZengMDPI AGMolecules1420-30492020-02-0125374210.3390/molecules25030742molecules25030742Sterically Stabilised Polymeric Mesoporous Silica Nanoparticles Improve Doxorubicin Efficiency: Tailored Cancer TherapyThashini Moodley0Moganavelli Singh1Nano-Gene and Drug Delivery Group, Discipline of Biochemistry, School of Life Sciences, University of Kwa-Zulu Natal, Private Bag X54001, Durban 4000, Kwa-Zulu Natal, South AfricaNano-Gene and Drug Delivery Group, Discipline of Biochemistry, School of Life Sciences, University of Kwa-Zulu Natal, Private Bag X54001, Durban 4000, Kwa-Zulu Natal, South AfricaThe fruition, commercialisation and clinical application combining nano-engineering, nanomedicine and material science for utilisation in drug delivery is becoming a reality. The successful integration of nanomaterial in nanotherapeutics requires their critical development to ensure physiological and biological compatibility. Mesoporous silica nanoparticles (MSNs) are attractive nanocarriers due to their biodegradable, biocompatible, and relative malleable porous frameworks that can be functionalized for enhanced targeting and delivery in a variety of disease models. The optimal formulation of an MSN with polyethylene glycol (2% and 5%) and chitosan was undertaken, to produce sterically stabilized, hydrophilic MSNs, capable of efficient loading and delivery of the hydrophobic anti-neoplastic drug, doxorubicin (DOX). The pH-sensitive release kinetics of DOX, together with the anticancer, apoptosis and cell-cycle activities of DOX-loaded MSNs in selected cancer cell lines were evaluated. MSNs of 36−60 nm in size, with a pore diameter of 9.8 nm, and a cumulative surface area of 710.36 m<sup>2</sup>/g were produced. The 2% pegylated MSN formulation (PCMSN) had the highest DOX loading capacity (0.98 mg<sub>dox</sub>/mg<sub>msn</sub>), and a sustained release profile over 72 h. Pegylated-drug nanoconjugates were effective at a concentration range between 20−50 μg/mL, inducing apoptosis in cancer cells, and affirming their potential as effective drug delivery vehicles.https://www.mdpi.com/1420-3049/25/3/742cancerdoxorubicindrug deliverymesoporous silica nanoparticleschitosanpolyethylene glycol |
spellingShingle | Thashini Moodley Moganavelli Singh Sterically Stabilised Polymeric Mesoporous Silica Nanoparticles Improve Doxorubicin Efficiency: Tailored Cancer Therapy Molecules cancer doxorubicin drug delivery mesoporous silica nanoparticles chitosan polyethylene glycol |
title | Sterically Stabilised Polymeric Mesoporous Silica Nanoparticles Improve Doxorubicin Efficiency: Tailored Cancer Therapy |
title_full | Sterically Stabilised Polymeric Mesoporous Silica Nanoparticles Improve Doxorubicin Efficiency: Tailored Cancer Therapy |
title_fullStr | Sterically Stabilised Polymeric Mesoporous Silica Nanoparticles Improve Doxorubicin Efficiency: Tailored Cancer Therapy |
title_full_unstemmed | Sterically Stabilised Polymeric Mesoporous Silica Nanoparticles Improve Doxorubicin Efficiency: Tailored Cancer Therapy |
title_short | Sterically Stabilised Polymeric Mesoporous Silica Nanoparticles Improve Doxorubicin Efficiency: Tailored Cancer Therapy |
title_sort | sterically stabilised polymeric mesoporous silica nanoparticles improve doxorubicin efficiency tailored cancer therapy |
topic | cancer doxorubicin drug delivery mesoporous silica nanoparticles chitosan polyethylene glycol |
url | https://www.mdpi.com/1420-3049/25/3/742 |
work_keys_str_mv | AT thashinimoodley stericallystabilisedpolymericmesoporoussilicananoparticlesimprovedoxorubicinefficiencytailoredcancertherapy AT moganavellisingh stericallystabilisedpolymericmesoporoussilicananoparticlesimprovedoxorubicinefficiencytailoredcancertherapy |